Biotech

11/12/21

Practical considerations for conducting a Series I IPO

Biotech

Finance

11/04/21

RA TV: How do we determine what a drug is worth?

Biotech

Policy

10/19/21

Vaccines and the inverted capital dilemma

Biotech

Culture

Finance

Science

10/12/21

Rational design of molecular glues — the next frontier

Biotech

Science

09/30/21

Innovation thrives in the spotlight

Biotech

Culture

Science

09/13/21

RA TV: Past, present, & future

Biotech

Science

09/09/21

And now for something completely different

Biotech

Culture

Science

09/07/21

Good or just successful? The Belichick conundrum

Biotech

Culture

08/26/21

RA TV: Aduhelm & Patient-Centered Healthcare Reforms

Biotech

Policy

Science

08/20/21

What happens if President Biden’s drug pricing plan passes?

Biotech

Policy

08/11/21

After binging on COVID-19, what have we missed?

Biotech

Culture

08/05/21

Biotechnology leadership is too valuable to throw away

Biotech

Policy

07/28/21

Investors and academics: making beautiful music together

Biotech

Culture

Finance

07/22/21

Accelerating life science tools R&D with venture studios

Biotech

Culture

Finance

Science

07/14/21

When drug prices are a Trojan Horse for other costs, we all lose

Biotech

Policy

07/08/21

RA TV: Vaccines versus variants

Biotech

Science

06/30/21

Four core principles for biotech board meetings

Biotech

Culture

06/24/21

Venture capital evolved to venture creation. Will it stay that way?

Biotech

Culture

Finance

06/24/21

Venture partnering

Biotech

Culture

09/15/20

The difference between medical debt and ​“moon debt”

Biotech

Culture

Policy